Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

D. F. Hayes, T. M. Walker, B. Singh, E. S. Vitetta, J. W. Uhr, S. Gross, C. Rao, G. V. Doyle, L. W. Terstappen

Research output: Contribution to journalArticle

137 Scopus citations

Abstract

Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

Original languageEnglish (US)
Pages (from-to)1111-1117
Number of pages7
JournalInternational journal of oncology
Volume21
Issue number5
DOIs
StatePublished - Nov 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.'. Together they form a unique fingerprint.

  • Cite this

    Hayes, D. F., Walker, T. M., Singh, B., Vitetta, E. S., Uhr, J. W., Gross, S., Rao, C., Doyle, G. V., & Terstappen, L. W. (2002). Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. International journal of oncology, 21(5), 1111-1117. https://doi.org/10.3892/ijo.21.5.1111